Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on

 Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock
   Updates, and Credit Facilities - Research Report on Forest Laboratories,
             Oxygen Biotherapeutics, Alimera, pSivida and AcelRx

PR Newswire

NEW YORK, December 24, 2013

NEW YORK, December 24, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Forest
Laboratories Inc. (NYSE: FRX), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT),
Alimera Sciences, Inc. (NASDAQ: ALIM), pSivida Corp. (NASDAQ: PSDV), and
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Forest Laboratories Inc. Research Report

On December 19, 2013, Forest Laboratories Inc. (Forest Laboratories) announced
the availability of FETZIMA™ (levomilnacipran ER capsules) in pharmacies
throughout the United States. The Company informed that FETZIMA was approved
by the U.S. Food and Drug Administration (FDA) for the treatment of Major
Depressive Disorder (MDD), also known as depression, in adults in July 2013.
Dr. Marco Taglietti, Executive Vice President, Drug Development & Research and
Chief Medical Officer of Forest Laboratories commented, "We are pleased to
announce that FETZIMA is now available to patients. Despite the number of
available antidepressant medications, the treatment of depression remains a
clinical challenge with a need for additional treatment options. In clinical
studies, patients who received FETZIMA vs. placebo experienced meaningful
improvement in their depressive symptoms and functional impairment. The
availability of FETZIMA is a significant step forward in our goal of bringing
a range of treatment options to adults living with MDD." The Full Research
Report on Forest Laboratories Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/ea24_FRX

Oxygen Biotherapeutics, Inc. Research Report

On December 11, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics)
announced its selection of Duke University's Duke Clinical Research Institute,
(DCRI) to conduct the Phase 3 trial of levosimendan, the Company's newly
acquired compound. The Company added that DCRI will serve as the coordinating
center and Drs. John H. Alexander and Rajendra Mehta will be lead
investigators for the Phase 3 trial. John Kelley, CEO for Oxygen
Biotherapeutics commented, "We are extremely pleased to have an organization
with the skill and expertise in conducting clinical trials that DCRI possesses
as our partner. They have been responsible for managing a number of major
cardiac surgery trials in the last decade, so their knowledge of this area of
medicine is invaluable to us." According to the Company, Phase 3 trial will be
conducted in approximately 50 major cardiac surgery centers in North America,
with enrollment expected to begin in the Q3 2014, and will take around 18
months to complete. The Full Research Report on Oxygen Biotherapeutics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5700_OXBT

Alimera Sciences, Inc. Research Report

On December 18, 2013, Alimera Sciences, Inc. (Alimera) announced that it has
entered into labeling discussions with the U.S. Food and Drug Administration
(FDA) for ILUVIEN®. The Company added that it has reached an agreement with
the FDA that Alimera's participation in the January 2014 Dermatologic and
Ophthalmic Advisory Committee meeting was not mandatory, and the Company will
focus on drafting its response to the Complete Response Letter received from
the FDA in October 2013 for submitting the response in Q1 2014. Dan Myers,
President and CEO of Alimera stated, "We are very pleased to have had the
opportunity to meet with the FDA to discuss appropriate labeling for ILUVIEN
and to determine the next steps required to move ILUVIEN closer to an FDA
approval. We are committed to addressing the remaining issues that were raised
in the CRL and plan to submit our response in the first quarter of 2014, which
will include recent safety data gathered from our patients in Europe." The
Full Research Report on Alimera Sciences, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/4440_ALIM

pSivida Corp. Research Report

On December 19, 2013, pSivida Corp.'s (pSivida) stock ended the day at $4.01,
representing a 35.02% rise compared to the previous day's closing price of
$2.97. The Company's stock rose 42.20% over the past three trading days,
compared to the Dow Jones Industrial Average, which went up by 1.85% over the
same trading period. The Full Research Report on pSivida Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/d4eb_PSDV

AcelRx Pharmaceuticals, Inc. Research Report

On December 19, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that it
has entered into a new amended and restated credit facility with Hercules
Technology Growth Capital, Inc. which provides for up to $40 million of new
loans. Richard King, President and CEO of AcelRx stated, "The proceeds from
this credit facility provide AcelRx with additional operating capital and
contingency funding for our commercialization activities as we continue to
prepare for the launch, if approved, of Zalviso™. These proceeds also provide
the financial flexibility to fund additional pipeline development programs
should we decide to advance any of our pipeline opportunities forward. We
appreciate the support of Hercules, and its confidence in Zalviso™ and the
AcelRx management team." The Full Research Report on AcelRx Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1454_ACRX

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.